RecruitingPhase 2NCT06085742

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

BRE-08: A Phase II Study of an All-Oral Adjuvant Chemotherapy Regimen of Cyclophosphamide, Methotrexate, and Capecitabine (CMC) for Early-Stage Breast Cancer

Sponsor

University of Illinois at Chicago

Enrollment

25 participants

Start Date

Nov 22, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a chemotherapy combination called CMC (cyclophosphamide, methotrexate, and capecitabine) as a treatment after surgery for early-stage breast cancer. Researchers want to find out if this regimen is effective for people who need additional treatment after their tumor has been removed. **You may be eligible if...** - You are 18 or older - You have been diagnosed with invasive breast cancer confirmed by biopsy - You had surgery to remove your breast tumor within the last 90 days - Your cancer has not spread to distant organs - Your doctor recommends chemotherapy after surgery (without concurrent targeted therapy) - You have not had prior chemotherapy or targeted therapy for this cancer **You may NOT be eligible if...** - Your cancer has spread to other parts of the body - You had prior systemic treatment other than endocrine (hormone) therapy before surgery - You are pregnant or breastfeeding - You have significant heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.